MR
Merus
MRUS · NASDAQ
$90.00 +0.00% (+$0.00)
Market Cap $6.83B
P/E Ratio -
Div. Yield -
ROE 48.76%
Piotroski F-Score Weak
3/9Valuation
0 /100
Expensive P/S 133.38x
P/B 10.32x
P/E N/A
Growth
80 /100
Growing Rev. growth 11.85%
Book val. growth 23.46%
EPS growth N/A
Profitability
0 /100
Weak Gross margin 217.50%
Net margin 654.44%
Op. margin 648.06%
Quality
1 /100
Poor ROIC 48.81%
ROE 48.76%
ROA 43.38%
Debt
95 /100
Low Debt/Equity 0.02x
Current ratio 7.97x
Net debt/EBITDA 0.94x
Stability
30 /100
Unstable Beta 1.06x
Rev. volatility 50.15%
EPS volatility 55.37%
Bulios Scoring opisuje jakość i historię firmy, a nie przyszły zwrot. Wysoki wynik to nie sygnał zakupu. Dowiedz się więcej
Zapytaj StockBota o MRUS
Online
O spółce
Merus N.V. is a Dutch biotechnology company focused on developing innovative immunotherapies for cancer treatment. The company is particularly known for its bispecific antibody technology, designed to selectively activate the immune system against cancer cells. Merus N.V. concentrates on developing treatments that can offer new hope to patients suffering from various types of cancer, including those who have failed other therapies.
Opis nie jest jeszcze dostępny w Twoim języku, więc tekst jest po angielsku.
Sector
Healthcare
Industry
Biotechnology
CEO
Jan van de Winkel
Employees
260
Headquarters
Utrecht